CM
AMRX icon

CastleKnight Management’s Amneal Pharmaceuticals AMRX Stock Holding History

CastleKnight Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-64,100
Closed -$407K – 361
2024
Q2 		$407K Sell
64,100
-35,400
-36% -$225K 0.02% 300
2024
Q1 		$603K Hold
99,500
– – 0.04% 242
2023
Q4 		$604K Buy
+99,500
New +$443K 0.03% 215

Other funds holding AMRX

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

CastleKnight Management's AMRX Position: Q3 2024 in Review

CastleKnight Management sold out of Amneal Pharmaceuticals (AMRX) in Q3 2024, closing a stake of 64,100 shares — an estimated $407K sold.

CastleKnight Management first reported a position in AMRX in Q4 2023 and held it in 3 quarters. The position peaked at $604K in Q4 2023. 182 funds tracked by Wall St. Rank hold AMRX as of Q3 2024.

  • CastleKnight Management reported no remaining Amneal Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • CastleKnight Management sold 64,100 Amneal Pharmaceuticals shares in Q3 2024, an estimated $407K.
  • CastleKnight Management first reported a position in Amneal Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • CastleKnight Management's Amneal Pharmaceuticals position peaked at $604K in Q4 2023.
  • 182 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2024.

Based on CastleKnight Management's 13F filing for Q3 2024, filed 14 Nov 2024.